Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NASDAQ:GTBP NASDAQ:IMMP NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.75+0.3%$1.86$1.54▼$5.50$60.29M1.19866,091 shs630,652 shsGTBPGT Biopharma$0.34-3.0%$0.43$0.26▼$2.29$15.32M0.84951,570 shs488,301 shsIMMPPrima BioMed$0.39+0.9%$0.42$0.29▼$3.53$57.31M2.23388,970 shs311,980 shsTCRXTScan Therapeutics$0.85-5.9%$0.98$0.83▼$2.57$58.80M1.04856,531 shs1.08 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+0.11%0.00%+1.16%-0.46%-33.78%GTBPGT Biopharma-3.01%-12.59%-32.12%+7.26%-84.19%IMMPPrima BioMed+0.90%-9.92%-0.38%-31.52%-76.64%TCRXTScan Therapeutics-5.92%-5.81%-8.10%-32.83%-54.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.75+0.3%$1.86$1.54▼$5.50$60.29M1.19866,091 shs630,652 shsGTBPGT Biopharma$0.34-3.0%$0.43$0.26▼$2.29$15.32M0.84951,570 shs488,301 shsIMMPPrima BioMed$0.39+0.9%$0.42$0.29▼$3.53$57.31M2.23388,970 shs311,980 shsTCRXTScan Therapeutics$0.85-5.9%$0.98$0.83▼$2.57$58.80M1.04856,531 shs1.08 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+0.11%0.00%+1.16%-0.46%-33.78%GTBPGT Biopharma-3.01%-12.59%-32.12%+7.26%-84.19%IMMPPrima BioMed+0.90%-9.92%-0.38%-31.52%-76.64%TCRXTScan Therapeutics-5.92%-5.81%-8.10%-32.83%-54.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.60Moderate Buy$11.67568.58% UpsideGTBPGT Biopharma 1.00SellN/AN/AIMMPPrima BioMed 2.00Hold$5.501,301.63% UpsideTCRXTScan Therapeutics 2.33Hold$6.00608.88% UpsideCurrent Analyst Ratings BreakdownLatest GTBP, TCRX, ANVS, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026TCRXTScan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/10/2026IMMPPrima BioMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/9/2026ANVSAnnovis Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/8/2026GTBPGT Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/7/2026ANVSAnnovis Bio Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/7/2026ANVSAnnovis Bio Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/6/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/23/2026TCRXTScan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$5.006/23/2026TCRXTScan Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.006/17/2026IMMPPrima BioMed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy4/29/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/AGTBPGT BiopharmaN/AN/A$0.01 per share23.10$0.23 per shareN/AIMMPPrima BioMed$6.69M8.64N/AN/A$0.63 per share0.62TCRXTScan Therapeutics$10.32M5.36N/AN/A$2.16 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%8/11/2026 (Estimated)GTBPGT Biopharma-$28.35M-$6.33N/AN/AN/AN/AN/A-102.03%8/13/2026 (Estimated)IMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)TCRXTScan Therapeutics-$129.77M-$0.96N/AN/AN/A-1,360.61%-91.94%-50.15%8/11/2026 (Estimated)Latest GTBP, TCRX, ANVS, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026GTBPGT Biopharma-$0.08N/AN/AN/AN/AN/A8/11/2026Q2 2026ANVSAnnovis Bio-$0.44N/AN/AN/AN/AN/A8/11/2026Q2 2026TCRXTScan Therapeutics-$0.29N/AN/AN/A$1.88 millionN/A5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/15/2026Q1 2026GTBPGT Biopharma-$0.08-$0.11-$0.03-$0.11N/AN/A5/6/2026Q1 2026TCRXTScan Therapeutics-$0.22-$0.22N/A-$0.22$2.50 million$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A1.271.27GTBPGT BiopharmaN/A4.144.14IMMPPrima BioMedN/A2.97N/ATCRXTScan Therapeutics0.346.656.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%GTBPGT Biopharma8.15%IMMPPrima BioMed2.32%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%GTBPGT Biopharma1.18%IMMPPrima BioMed3.07%TCRXTScan Therapeutics6.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableGTBPGT Biopharma844.34 million43.82 millionNo DataIMMPPrima BioMed2,021147.37 million142.85 millionOptionableTCRXTScan Therapeutics10065.35 million61.27 millionNot OptionableGTBP, TCRX, ANVS, and IMMP HeadlinesRecent News About These CompaniesCritical Comparison: Seres Therapeutics (NASDAQ:MCRB) versus TScan Therapeutics (NASDAQ:TCRX)July 20, 2026 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by BrokeragesJuly 19, 2026 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Hold" from AnalystsJuly 19, 2026 | marketbeat.comTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 24, 2026 | globenewswire.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...June 23, 2026 | markets.businessinsider.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationJune 22, 2026 | globenewswire.comCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesJune 3, 2026 | businesswire.comTScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net LossJune 2, 2026 | insidermonkey.comTScan Therapeutics Expands Authorized Shares After Stockholder VoteMay 22, 2026 | tipranks.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingApril 27, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.40%April 18, 2026 | aaii.comATScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comTScan Therapeutics Consolidates Finance Leadership After Officer ResignationApril 2, 2026 | tipranks.comStrong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy SpaceMarch 25, 2026 | insidermonkey.comTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesMarch 4, 2026 | zacks.comTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 4, 2026 | globenewswire.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...February 26, 2026 | markets.businessinsider.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03February 26, 2026 | globenewswire.comTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTBP, TCRX, ANVS, and IMMP Company DescriptionsAnnovis Bio NYSE:ANVS$1.74 +0.01 (+0.29%) Closing price 07/23/2026 03:59 PM EasternExtended Trading$1.75 +0.00 (+0.29%) As of 07/23/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.GT Biopharma NASDAQ:GTBP$0.34 -0.01 (-3.01%) Closing price 07/23/2026 04:00 PM EasternExtended Trading$0.33 -0.01 (-1.85%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Prima BioMed NASDAQ:IMMP$0.39 +0.00 (+0.90%) Closing price 07/23/2026 04:00 PM EasternExtended Trading$0.39 +0.00 (+0.15%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.TScan Therapeutics NASDAQ:TCRX$0.85 -0.05 (-5.92%) Closing price 07/23/2026 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.37%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Alphabet Crushed Earnings, But One Number Spooked the Market Premium Retail’s Stress Test Is Separating Winners From Losers GE Vernova Just Sent a Mixed AI Signal to Investors Otis Took Another Guidance Cut—But the Story Isn't Over Philip Morris Trimmed Guidance, But Its Growth Story Looks Unshaken The 2026 Blueprint: 6 Stocks for a Brand New Portfolio Cementing the Sky: Why NVIDIA’s Bet on Nebius Matters Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
